This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Full risk management plan(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion on any scientific matter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- Advanced therapies(398)
- Antimicrobial resistance(46)
- Biologicals(24)
- Biosimilars(151)
- Brexit(30)
- Careers(3)
- Clinical trials(185)
- Compassionate use(4)
- Compliance and inspections(105)
- Corporate(51)
- COVID-19(466)
- Data on medicines(169)
- Early access(25)
- Fees(13)
- Generic and hybrid medicines(400)
- Governance(91)
- Innovation(281)
- Maximum residue limit(17)
- Medication error(6)
- Medicines(7829)
- Medicines for use outside the EU(29)
- Medicine shortages(126)
- Mpox(17)
- Paediatrics(3123)
- Parallel distribution(6)
- Pharmacovigilance(2935)
- Procurement(10)
- Product information(61)
- Quality of medicines(85)
- Rare diseases(3275)
- Referrals(381)
- Regulatory and procedural guidance(552)
- Research and development(228)
- Scientific advice(38)
- Scientific guidelines(1014)
- SME(63)
- Vaccines(382)
- Veterinary limited markets(15)
Search results (24232)
Decision type:
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area:
Infectious diseases
PIP number:
P/0219/2023
Route(s) of administration:
Intravenous use
Pharmaceutical form(s):
Concentrate for solution for infusion
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
Decision type:
W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area:
Oncology
PIP number:
P/0239/2023
Route(s) of administration:
Oral use
Pharmaceutical form(s):
Tablet
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
Decision type:
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area:
Immunology-Rheumatology-Transplantation
PIP number:
P/0208/2023
Route(s) of administration:
Subcutaneous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check:
✖
PIPHuman
Online
European Medicines Agency, Amsterdam, the Netherlands
Start date:
18 July 2024, 11:00 (CEST)
End date:
18 July 2024, 12:00 (CEST)
EventHumanVeterinary
Tofersen
Amyotrophic Lateral Sclerosis
Date of authorisation:
Revision:
1
Last updated:
MedicineHumanAuthorised
azacitidine
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute
Date of authorisation:
Revision:
8
Last updated:
MedicineHumanAuthorised
filgotinib
Arthritis, Rheumatoid
Date of authorisation:
Revision:
11
Last updated:
MedicineHumanAuthorised
leuprorelin
Prostatic Neoplasms
Date of authorisation:
Revision:
4
Last updated:
MedicineHumanAuthorised
temsirolimus
Carcinoma, Renal Cell
Lymphoma, Mantle-Cell
Date of authorisation:
Revision:
34
Last updated:
MedicineHumanAuthorised
The European Medicines Agency (EMA) makes upgrades to this website from time to time, to improve user experience. During these upgrades, the website is unavailable for a short period of time, outside of EMA working hours. This page lists when we are planning the next outage and the main improvements made.
Last updated:
Corporate